当前位置: 首页 >> 检索结果
共有 9900 条符合本次的查询结果, 用时 2.1559211 秒

461. Clinical trials: Glucosamine-chondroitin combo improves knee OA pain.

作者: Sarah Onuora.
来源: Nat Rev Rheumatol. 2015年11卷3期126页

462. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres.

作者: Cristina Pamfil.;Antonis Fanouriakis.;Laura Damian.;Mirela Rinzis.;Prodromos Sidiropoulos.;Georgios Tsivgoulis.;Simona Rednic.;George Bertsias.;Dimitrios T Boumpas.
来源: Rheumatology (Oxford). 2015年54卷7期1270-8页
To compare the European League Against Rheumatism (EULAR) recommendations for the management of NPSLE with usual care in two tertiary centres and to detect potential pitfalls in their use for diagnosis and treatment.

463. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.

作者: Lianne Kearsley-Fleet.;Kimme L Hyrich.;Rebecca Davies.;Mark Lunt.;Taunton R Southwood.; .
来源: Rheumatology (Oxford). 2015年54卷7期1279-85页
Children with JIA can experience delayed and restricted growth. The objectives of this study were to investigate the influence of etanercept (ETN) on vertical growth and factors associated with improved growth in patients with JIA over the initial 2 years of treatment.

464. Osteoarthritis: What is the evidence for valgus bracing effects in knee OA?

作者: Kim L Bennell.;Rana S Hinman.
来源: Nat Rev Rheumatol. 2015年11卷3期132-4页

465. Rheumatoid arthritis: Another cog in the mechanism of methotrexate.

作者: Nicholas J Bernard.
来源: Nat Rev Rheumatol. 2015年11卷3期127页

466. Rheumatoid arthritis. The two faces of Rsk2 in hyperplastic disease.

作者: Jane Falconer.;Christopher D Buckley.
来源: Nat Rev Rheumatol. 2015年11卷4期203-5页
Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?

467. Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice.

作者: Emilio Besada.
来源: Rheumatology (Oxford). 2015年54卷4期751页

468. Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice: reply.

作者: Clémentine Fortunet.;Jean Francis Maillefert.
来源: Rheumatology (Oxford). 2015年54卷4期751-2页

469. Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice.

作者: Hsiu-Jung Liao.;I-Tsu Chyuan.;Chien-Sheng Wu.;Shu-Wha Lin.;Kun-Hung Chen.;Hwei-Fang Tsai.;Ping-Ning Hsu.
来源: Rheumatology (Oxford). 2015年54卷7期1317-26页
Proline-serine-threonine-phosphatase-interacting protein 2 (PSTPIP2) is involved in macrophage activation, neutrophil motility and osteoclast differentiation. However, the role of PSTPIP2 in inflammation and autoinflammatory diseases is still not clear. In this study, we generated PSTPIP2 knockout (Pstpip2(-/-)) mice to investigate its phenotype and role in autoinflammatory diseases.

470. Abnormalities of selenium but not of copper homeostasis may drive tissue fibrosis in patients with systemic sclerosis.

作者: Michael Hughes.;Garth J S Cooper.;Jack Wilkinson.;Paul New.;John M Guy.;Ariane L Herrick.
来源: Rheumatology (Oxford). 2015年54卷4期747-8页

471. Reply: HR-pQCT has promise in rheumatology.

作者: Emilio Filippucci.;Luca Di Geso.;Walter Grassi.
来源: Nat Rev Rheumatol. 2015年11卷2期123页

472. High-resolution peripheral quantitative CT in rheumatology.

作者: Cheryl Barnabe.;Stephanie Finzel.;Kathryn S Stok.;Piet Geusens.
来源: Nat Rev Rheumatol. 2015年11卷2期123页

473. A new look at rheumatology in China--opportunities and challenges.

作者: Zhan-Guo Li.
来源: Nat Rev Rheumatol. 2015年11卷5期313-7页
In the past two decades, Chinese rheumatology has developed rapidly in terms of both clinical practice and basic research. Many rheumatology departments and divisions have been established, creating positions for more residents to join rheumatology practices. Numerous studies of rheumatic diseases have been published in recent years by Chinese rheumatologists and immunologists, supported by government funding that has dramatically increased over the past few years. These studies are focused mainly on epidemiology, mechanisms, early diagnosis and interventions of rheumatic diseases. Increasing numbers of national and international scientific activities in China, including research collaborations, education programmes and conferences have greatly helped the development of rheumatology. In this APLAR series article, the major, high-impact studies and latest developments in Chinese rheumatology are reviewed.

474. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population.

作者: Eric Hachulla.;Pierre Clerson.;Paolo Airò.;Giovanna Cuomo.;Yannick Allanore.;Paola Caramaschi.;Edoardo Rosato.;Patricia E Carreira.;Valeria Riccieri.;Marta Sarraco.;Christopher P Denton.;Gabriela Riemekasten.;Maria Rosa Pozzi.;Silvana Zeni.;Carmen Marina Mihai.;Susanne Ullman.;Oliver Distler.;Simona Rednic.;Vanessa Smith.;Ulrich A Walker.;Marco Matucci-Cerinic.;Ulf Müller-Ladner.;David Launay.; .
来源: Rheumatology (Oxford). 2015年54卷7期1262-9页
The aim of this study was to assess the prognostic value of systolic pulmonary artery pressure (sPAP) estimated by echocardiography in the multinational European League Against Rheumatism Scleroderma Trial and Research (EUSTAR) cohort.

475. Non-steroidal anti-inflammatory drugs and venous thromboembolism.

作者: Nicola Alcorn.;Rajan Madhok.
来源: Rheumatology (Oxford). 2015年54卷4期570-1页

476. Aortic Atherosclerosis in Systemic Lupus Erythematosus.

作者: Paola C Roldan.;Michelle Ratliff.;Richard Snider.;Leonardo Macias.;Rodrigo Rodriguez.;Wilmer Sibbitt.;Carlos A Roldan.
来源: Rheumatology (Sunnyvale). 2014年Suppl 5卷
Aortic atherosclerosis (AoA) defined as intima-media thickening or plaques and aortic stiffness (AoS) also considered an atherosclerotic process and defined as decreased vessel distensibility (higher pulse pressure to achieve similar degree of vessel distension) are common in patients with SLE. Immune-mediated inflammation, thrombogenesis, traditional atherogenic factors, and therapy-related metabolic abnormalities are the main pathogenic factors of AoA and AoS. Pathology of AoA and AoS suggests an initial subclinical endothelialitis or vasculitis, which is exacerbated by thrombogenesis and atherogenic factors and ultimately resulting in AoA and AoS. Computed tomography (CT) for detection of arterial wall calcifications and arterial tonometry for detection of increased arterial pulse wave velocity are the most common diagnostic methods for detecting AoA and AoS, respectively. MRI may become a more applicable and accurate technique than CT. Although transesophageal echocardiography accurately detects earlier and advanced stages of AoA and AoS, it is semi-invasive and cannot be used as a screening method. Although imaging techniques demonstrate highly variable prevalence rates, on average about one third of adult SLE patients may have AoA or AoS. Age at SLE diagnosis; SLE duration; activity and damage; corticosteroid therapy; metabolic syndrome; chronic kidney disease; and mitral annular calcification are common independent predictors of AoA and AoS. Also, AoA and AoS are highly associated with carotid and coronary atherosclerosis. Earlier stages of AoA and AoS are usually subclinical. However, earlier stages of disease may be causally related or contribute to peripheral or cerebral embolism, pre-hypertension and hypertension, and increased left ventricular afterload resulting in left ventricular hypertrophy and diastolic dysfunction. Later stages of disease predisposes to visceral ischemia, aortic aneurysms and aortic dissection. Even earlier stages of AoA and AoS have been associated with increased cardiovascular and cerebrovascular morbidity and mortality of SLE patients. Aggressive non-steroidal immunosuppressive therapy and non-pharmacologic and pharmacologic interventions for control of atherogenic risk factors may prevent the development or progression of AoA and AoS and may decrease cardiovascular and cerebrovascular morbidity and mortality in SLE.

477. IgG4-related periaortitis vs idiopathic periaortitis: is there a role for atherosclerotic plaque in the pathogenesis of IgG4-related periaortitis?

作者: Thomas Castelein.;Walter Coudyzer.;Daniel Blockmans.
来源: Rheumatology (Oxford). 2015年54卷7期1250-6页
The diagnosis of (isolated) IgG4-related periaortitis is often based on elevated serum IgG4 levels since in tissues such as the aorta, biopsies cannot be easily performed. However, the role for serum IgG4 as a biomarker for IgG4-related periaortitis is indistinct. The main purpose of our study was to identify clinical differences between periaortitis with elevated vs normal serum IgG4 levels.

478. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?

作者: Lodewijk de Groot.;Nynke A Jager.;Johanna Westra.;Andries J Smit.;Cees G M Kallenberg.;Marcel D Posthumus.;Marc Bijl.
来源: Rheumatology (Oxford). 2015年54卷7期1257-61页
The incidence of cardiovascular disease (CVD) is increased in RA. This study was designed to evaluate whether a reduction in disease activity influences early markers of CVD.

479. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.

作者: Yi-Ming Chen.;Ching-Heng Lin.;Tsuo-Hung Lan.;Hsin-Hua Chen.;Shih-Ni Chang.;Yi-Hsing Chen.;Jun-Sing Wang.;Wei-Ting Hung.;Joung-Liang Lan.;Der-Yuan Chen.
来源: Rheumatology (Oxford). 2015年54卷7期1244-9页
SLE is associated with increased risk of diabetes mellitus. Treatment for SLE requires high-dose glucocorticoids that may worsen glucose homoeostasis. HCQ can reduce diabetes risk in RA. This study aimed to investigate the association of HCQ use and diabetes mellitus risk in SLE patients.

480. A pathogenetic role for IL-21 in primary Sjögren syndrome.

作者: Seung-Ki Kwok.;Jennifer Lee.;Di Yu.;Kwi Young Kang.;Mi-La Cho.;Hae-Rim Kim.;Ji Hyeon Ju.;Sang-Heon Lee.;Sung-Hwan Park.;Ho-Youn Kim.
来源: Nat Rev Rheumatol. 2015年11卷6期368-74页
Advances in our understanding of the pathogenesis of primary Sjögren syndrome (pSS) characterize it as a highly complex process encompassing both the initiation of innate immunity and subsequent adaptive immune responses. IL-21 is receiving attention as a potential key player in the pathogenesis of pSS owing to its pleiotropic effects on the type I interferon signalling pathway, and newly identified roles in generation of follicular and IL-17-producing subtypes of helper T cells, as well as plasma-cell differentiation and B-cell activation. Taking into consideration the diverse biological functions of IL-21 and its clinical relevance to pSS, we propose that this cytokine has a central role in orchestrating the complex immune response in pSS. This hypothesis might provide new insight into the pathogenesis of pSS and facilitate the development of effective therapeutic strategies.
共有 9900 条符合本次的查询结果, 用时 2.1559211 秒